Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

This study has been terminated.
(Business decision not to continue development)
Information provided by (Responsible Party):
Hospira, now a wholly owned subsidiary of Pfizer Identifier:
First received: June 26, 2007
Last updated: January 10, 2012
Last verified: January 2012
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.

Condition Intervention Phase
Drug: PMI-150 (intranasal ketamine)
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Comparing the Efficacy and Safety of PMI-150 (Intranasal Ketamine) to Placebo as an Analgesic for the Treatment of Breakthrough Pain in Cancer Patients

Resource links provided by NLM:

Further study details as provided by Hospira, now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • pain intensity difference [ Time Frame: 60 minutes ]

Secondary Outcome Measures:
  • various pain assessments [ Time Frame: 60 minutes ]

Enrollment: 2
Study Start Date: June 2007
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
PMI-150 (intranasal ketamine)
Drug: PMI-150 (intranasal ketamine)
intranasal dosing
Placebo Comparator: B
Drug: placebo

Detailed Description:
The primary objective is to evaluate the safety and efficacy following the administration of intranasal ketamine in providing pain relief as compared to placebo.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • at least 18 years of age
  • Patients requiring around-the-clock opioids for pain due to cancer and with a history of experiencing episodes of breakthrough pain

Exclusion Criteria:

  • under 18 years
  • non-cancer pain
  • allergy to ketamine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00492388

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Hospira, now a wholly owned subsidiary of Pfizer
Principal Investigator: Zahid Bajwa, MD Beth Israel Deaconess Medical Center
  More Information

Responsible Party: Hospira, now a wholly owned subsidiary of Pfizer Identifier: NCT00492388     History of Changes
Other Study ID Numbers: KET-016
Study First Received: June 26, 2007
Last Updated: January 10, 2012

Keywords provided by Hospira, now a wholly owned subsidiary of Pfizer:

Additional relevant MeSH terms:
Breakthrough Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017